Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany
· Delayed Price · Currency is EUR 0.2140
-0.0060 (-2.73%)
At close: Aug 15, 2025
Northwest Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -82.32 | -83.78 | -62.6 | -105.03 | 179.13 | -529.82 | Upgrade
|
| Depreciation & Amortization | 2.04 | 2.04 | 1.73 | 1.5 | 0.59 | 0.43 | Upgrade
|
| Other Amortization | 2.27 | 2.48 | 2.37 | 2.77 | 2.3 | 3.01 | Upgrade
|
| Stock-Based Compensation | 1.89 | 3.46 | 4.41 | 12.3 | 15.5 | 52.21 | Upgrade
|
| Other Operating Activities | 14.46 | 8.78 | 4.14 | 28.48 | -238.54 | 442.12 | Upgrade
|
| Change in Accounts Payable | 16.81 | 9.85 | -4.43 | 6.85 | -0.6 | 2.13 | Upgrade
|
| Change in Other Net Operating Assets | 0.33 | 0.16 | 0.73 | 0.36 | 3.32 | -2.17 | Upgrade
|
| Operating Cash Flow | -44.52 | -57.02 | -53.64 | -52.78 | -38.3 | -32.09 | Upgrade
|
| Capital Expenditures | -0.65 | -1.01 | -3.44 | -2.9 | -6.02 | -6.61 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | -1.53 | Upgrade
|
| Investing Cash Flow | -0.65 | -1.01 | -3.44 | -2.9 | -6.02 | -8.14 | Upgrade
|
| Short-Term Debt Issued | - | 0.2 | 0.01 | 2.57 | 0.25 | 0.32 | Upgrade
|
| Long-Term Debt Issued | - | 34.02 | 33.34 | 5.6 | 29.67 | 13.67 | Upgrade
|
| Total Debt Issued | 29.62 | 34.22 | 33.35 | 8.17 | 29.92 | 13.99 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -0.38 | Upgrade
|
| Long-Term Debt Repaid | - | -1.43 | -0.39 | -5.49 | -5.83 | -1.65 | Upgrade
|
| Total Debt Repaid | -1.98 | -1.43 | -0.39 | -5.49 | -5.83 | -2.02 | Upgrade
|
| Net Debt Issued (Repaid) | 27.65 | 32.78 | 32.96 | 2.68 | 24.09 | 11.96 | Upgrade
|
| Issuance of Common Stock | 23.83 | 15.75 | 1.72 | 20.57 | 24.05 | 40.73 | Upgrade
|
| Other Financing Activities | - | 0.05 | 4.75 | - | - | 0 | Upgrade
|
| Financing Cash Flow | 51.74 | 56.79 | 52.76 | 41.97 | 48.13 | 52.7 | Upgrade
|
| Foreign Exchange Rate Adjustments | -5.14 | 1.3 | -0.52 | 5.51 | 1.37 | -2.85 | Upgrade
|
| Net Cash Flow | 1.44 | 0.05 | -4.84 | -8.2 | 5.19 | 9.61 | Upgrade
|
| Free Cash Flow | -45.17 | -58.03 | -57.07 | -55.68 | -44.31 | -38.7 | Upgrade
|
| Free Cash Flow Margin | -4128.98% | -4199.06% | -2954.14% | -3308.20% | -4409.35% | -2997.91% | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.05 | -0.05 | -0.06 | -0.04 | -0.05 | Upgrade
|
| Cash Interest Paid | 0.34 | 0.13 | 0.06 | 0.91 | 1.73 | 0.04 | Upgrade
|
| Levered Free Cash Flow | -22.22 | -30.19 | -118.13 | -44.98 | -270 | 325.19 | Upgrade
|
| Unlevered Free Cash Flow | -19.49 | -27.81 | -117.23 | -43.96 | -269.17 | 327.52 | Upgrade
|
| Change in Working Capital | 17.14 | 10 | -3.7 | 7.21 | 2.73 | -0.04 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.